{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T23:48:50Z","timestamp":1789602530651,"version":"build-2803163510"},"reference-count":234,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R56DK084045"],"award-info":[{"award-number":["R56DK084045"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.bone.2021.116060","type":"journal-article","created":{"date-parts":[[2021,6,16]],"date-time":"2021-06-16T06:38:38Z","timestamp":1623825518000},"page":"116060","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["RASopathies: The musculoskeletal consequences and their etiology and pathogenesis"],"prefix":"10.1016","volume":"152","author":[{"given":"John L.","family":"Fowlkes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn M.","family":"Thrailkill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Clay","family":"Bunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2021.116060_bb0005","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1146\/annurev-genom-091212-153523","article-title":"The RASopathies","volume":"14","author":"Rauen","year":"2013","journal-title":"Annu. Rev. Genomics Hum. Genet."},{"issue":"3","key":"10.1016\/j.bone.2021.116060_bb0010","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.gde.2009.04.001","article-title":"The RASopathies: developmental syndromes of Ras\/MAPK pathway dysregulation","volume":"19","author":"Tidyman","year":"2009","journal-title":"Curr. Opin. Genet. Dev."},{"issue":"12","key":"10.1016\/j.bone.2021.116060_bb0015","first-page":"1","volume":"6","year":"1987","journal-title":"Natl. Inst. Health Consens. Dev. Conf. Consens. Statement"},{"key":"10.1016\/j.bone.2021.116060_bb0020","series-title":"Neurofibromatosis","first-page":"172","volume":"1(3)","author":"National Institutes of Health Consensus Development Conference Statement: neurofibromatosis. Bethesda, Md., USA, July 13\u2013-15, 1987","year":"1988"},{"issue":"5","key":"10.1016\/j.bone.2021.116060_bb0025","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2019-0660","article-title":"Health supervision for children with Neurofibromatosis Type 1","volume":"143","author":"Miller","year":"2019","journal-title":"Pediatrics"},{"issue":"6","key":"10.1016\/j.bone.2021.116060_bb0030","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.mcna.2019.07.004","article-title":"The diagnosis and Management of Neurofibromatosis Type 1","volume":"103","author":"Ly","year":"2019","journal-title":"Med. Clin. North Am."},{"issue":"11","key":"10.1016\/j.bone.2021.116060_bb0035","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/ejhg.2011.113","article-title":"Mortality in neurofibromatosis 1: in North West England: an assessment of actuarial survival in a region of the UK since 1989","volume":"19","author":"Evans","year":"2011","journal-title":"Eur. J. Hum. Genet."},{"issue":"2","key":"10.1016\/j.bone.2021.116060_bb0040","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/ajmg.a.33139","article-title":"Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service","volume":"152A","author":"Evans","year":"2010","journal-title":"Am. J. Med. Genet. A"},{"issue":"1","key":"10.1016\/j.bone.2021.116060_bb0045","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1542\/peds.2007-3204","article-title":"Neurofibromatosis type 1 revisited","volume":"123","author":"Williams","year":"2009","journal-title":"Pediatrics"},{"issue":"1","key":"10.1016\/j.bone.2021.116060_bb0050","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/MOP.0b013e32834230ce","article-title":"Orthopaedic aspects of neurofibromatosis: update","volume":"23","author":"Delucia","year":"2011","journal-title":"Curr. Opin. Pediatr."},{"issue":"Suppl. 2","key":"10.1016\/j.bone.2021.116060_bb0055","first-page":"289","article-title":"Growth and pubertal disorders in neurofibromatosis type 1","volume":"16","author":"Virdis","year":"2003","journal-title":"J. Pediatr. Endocrinol. Metab."},{"issue":"12","key":"10.1016\/j.bone.2021.116060_bb0060","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1136\/jmg.37.12.933","article-title":"Growth in North American white children with neurofibromatosis 1 (NF1)","volume":"37","author":"Szudek","year":"2000","journal-title":"J. Med. Genet."},{"issue":"2","key":"10.1016\/j.bone.2021.116060_bb0065","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1136\/jnnp.2010.206532","article-title":"The neurofibromatoses","volume":"10","author":"Ferner","year":"2010","journal-title":"Pract. Neurol."},{"issue":"3","key":"10.1016\/j.bone.2021.116060_bb0070","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1177\/0883073812446310","article-title":"Height assessments in children with neurofibromatosis type 1","volume":"28","author":"Soucy","year":"2013","journal-title":"J. Child Neurol."},{"issue":"5","key":"10.1016\/j.bone.2021.116060_bb0075","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0887-8994(00)00123-5","article-title":"Growth hormone deficiency in children with neurofibromatosis type 1 without suprasellar lesions","volume":"22","author":"Vassilopoulou-Sellin","year":"2000","journal-title":"Pediatr. Neurol."},{"issue":"12","key":"10.1016\/j.bone.2021.116060_bb0080","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1177\/0883073818786807","article-title":"Height growth impairment in children with Neurofibromatosis type 1 is characterized by decreased pubertal growth velocity in both sexes","volume":"33","author":"Zessis","year":"2018","journal-title":"J. Child Neurol."},{"issue":"12","key":"10.1016\/j.bone.2021.116060_bb0085","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1002\/ajmg.a.31754","article-title":"Associations of osseous abnormalities in Neurofibromatosis 1","volume":"143A","author":"Alwan","year":"2007","journal-title":"Am. J. Med. Genet. A"},{"issue":"3","key":"10.1016\/j.bone.2021.116060_bb0090","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/01.bpo.0000217719.10728.39","article-title":"Neurofibromatosis update","volume":"26","author":"Crawford","year":"2006","journal-title":"J. Pediatr. Orthop."},{"issue":"9","key":"10.1016\/j.bone.2021.116060_bb0095","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1590\/S0100-879X2005000900020","article-title":"High frequencies of plexiform neurofibromas, mental retardation, learning difficulties, and scoliosis in Brazilian patients with neurofibromatosis type 1","volume":"38","author":"Trovo-Marqui","year":"2005","journal-title":"Braz. J. Med. Biol. Res."},{"issue":"4","key":"10.1016\/j.bone.2021.116060_bb0100","doi-asserted-by":"crossref","first-page":"103815","DOI":"10.1016\/j.ejmg.2019.103815","article-title":"Severe thoracic and spinal bone abnormalities in neurofibromatosis type 1","volume":"63","author":"Prudhomme","year":"2020","journal-title":"Eur. J. Med. Genet."},{"key":"10.1016\/j.bone.2021.116060_bb0105","doi-asserted-by":"crossref","first-page":"17004","DOI":"10.1038\/nrdp.2017.4","article-title":"Neurofibromatosis type 1","volume":"3","author":"Gutmann","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"1","key":"10.1016\/j.bone.2021.116060_bb0110","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/00007632-200001010-00013","article-title":"Modulation of spinal deformities in patients with neurofibromatosis type 1","volume":"25","author":"Durrani","year":"2000","journal-title":"Spine (Phila Pa 1976)"},{"issue":"3","key":"10.1016\/j.bone.2021.116060_bb0115","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/ajmg.a.33851","article-title":"Variable expression of neurofibromatosis 1 in monozygotic twins","volume":"155A","author":"Rieley","year":"2011","journal-title":"Am. J. Med. Genet. A"},{"issue":"9","key":"10.1016\/j.bone.2021.116060_bb0120","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s00431-016-2757-z","article-title":"Prevalence of neurofibromatosis type 1 in congenital pseudarthrosis of the tibia","volume":"175","author":"Van Royen","year":"2016","journal-title":"Eur. J. Pediatr."},{"issue":"10","key":"10.1016\/j.bone.2021.116060_bb0125","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1002\/humu.23783","article-title":"Neurofibromatosis type 1-related pseudarthrosis: beyond the pseudarthrosis site","volume":"40","author":"Brekelmans","year":"2019","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.bone.2021.116060_bb0130","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1146\/annurev-pathol-052016-100228","article-title":"Dissecting clinical heterogeneity in neurofibromatosis type 1","volume":"12","author":"Monroe","year":"2017","journal-title":"Annu. Rev. Pathol."},{"issue":"5","key":"10.1016\/j.bone.2021.116060_bb0135","first-page":"1751","article-title":"Dysplasia of the orbit and adjacent bone associated with plexiform neurofibroma and ocular disease in 42 NF-1 patients","volume":"30","author":"Friedrich","year":"2010","journal-title":"Anticancer Res."},{"issue":"1","key":"10.1016\/j.bone.2021.116060_bb0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ajmg.a.36793","article-title":"Recent developments in neurofibromatoses and RASopathies: management, diagnosis and current and future therapeutic avenues","volume":"167A","author":"Rauen","year":"2015","journal-title":"Am. J. Med. Genet. A"},{"issue":"1","key":"10.1016\/j.bone.2021.116060_bb0145","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jpeds.2006.10.048","article-title":"Bone mineral density in children and adolescents with neurofibromatosis type 1","volume":"150","author":"Stevenson","year":"2007","journal-title":"J. Pediatr."},{"issue":"6","key":"10.1016\/j.bone.2021.116060_bb0150","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1530\/ERC-12-0293","article-title":"Bone mineral density in children and young adults with neurofibromatosis type 1","volume":"19","author":"Lodish","year":"2012","journal-title":"Endocr. Relat. Cancer"},{"issue":"1","key":"10.1016\/j.bone.2021.116060_bb0155","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jocd.2009.10.002","article-title":"Quantitative ultrasound and dual-energy x-ray absorptiometry in children and adolescents with neurofibromatosis of type 1","volume":"13","author":"Caffarelli","year":"2010","journal-title":"J. Clin. Densitom."},{"issue":"1","key":"10.1016\/j.bone.2021.116060_bb0160","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ymgme.2007.12.004","article-title":"Generalized metabolic bone disease in Neurofibromatosis type I","volume":"94","author":"Brunetti-Pierri","year":"2008","journal-title":"Mol. Genet. Metab."},{"issue":"4","key":"10.1016\/j.bone.2021.116060_bb0165","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1097\/01.bpb.0000271310.87997.ae","article-title":"Decreased bone mineral density in neurofibromatosis type 1: results from a pediatric cohort","volume":"27","author":"Dulai","year":"2007","journal-title":"J. Pediatr. Orthop."},{"issue":"2","key":"10.1016\/j.bone.2021.116060_bb0170","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1515\/jpem-2016-0092","article-title":"Bone mineral density and bone metabolic markers\u2019 status in children with neurofibromatosis type 1","volume":"30","author":"Poyrazoglu","year":"2017","journal-title":"J. Pediatr. Endocrinol. Metab."},{"issue":"4","key":"10.1016\/j.bone.2021.116060_bb0175","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1136\/jmg.2008.061895","article-title":"Bone health and fracture rate in individuals with neurofibromatosis 1 (NF1)","volume":"46","author":"Tucker","year":"2009","journal-title":"J. Med. Genet."},{"issue":"4","key":"10.1016\/j.bone.2021.116060_bb0180","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s00403-011-1191-3","article-title":"Bone mineral metabolism in patients with neurofibromatosis type 1 (von Recklingausen disease)","volume":"304","author":"Petramala","year":"2012","journal-title":"Arch. Dermatol. Res."},{"issue":"1","key":"10.1016\/j.bone.2021.116060_bb0185","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00223-012-9661-y","article-title":"Neurofibromatosis 1-related osteopenia often progresses to osteoporosis in 12 years","volume":"92","author":"Heerva","year":"2013","journal-title":"Calcif. Tissue Int."},{"issue":"11","key":"10.1016\/j.bone.2021.116060_bb0190","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1002\/jbmr.1685","article-title":"A controlled register-based study of 460 neurofibromatosis 1 patients: increased fracture risk in children and adults over 41 years of age","volume":"27","author":"Heerva","year":"2012","journal-title":"J. Bone Miner. Res."},{"issue":"1","key":"10.1016\/j.bone.2021.116060_bb0195","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0086115","article-title":"Multiscale, converging defects of macro-porosity, microstructure and matrix mineralization impact long bone fragility in NF1","volume":"9","author":"Kuhnisch","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.bone.2021.116060_bb0200","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00198-009-0933-y","article-title":"High bone turnover and accumulation of osteoid in patients with neurofibromatosis 1","volume":"21","author":"Seitz","year":"2010","journal-title":"Osteoporos. Int."},{"issue":"2","key":"10.1016\/j.bone.2021.116060_bb0205","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00223-018-0488-z","article-title":"Trabecular Bone Score (TBS) and bone metabolism in patients affected with Type 1 Neurofibromatosis (NF1)","volume":"104","author":"Filopanti","year":"2019","journal-title":"Calcif. Tissue Int."},{"issue":"8","key":"10.1016\/j.bone.2021.116060_bb0210","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1007\/s00198-004-1801-4","article-title":"Decreased bone mineral density and content in neurofibromatosis type 1: lowest local values are located in the load-carrying parts of the body","volume":"16","author":"Kuorilehto","year":"2005","journal-title":"Osteoporos. Int."},{"issue":"4","key":"10.1016\/j.bone.2021.116060_bb0215","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1001\/archpedi.1968.02100020377005","article-title":"Hypertelorism with Turner phenotype. A new syndrome with associated congenital heart disease","volume":"116","author":"Noonan","year":"1968","journal-title":"Am. J. Dis. Child"},{"key":"10.1016\/j.bone.2021.116060_bb0220","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1146\/annurev.genom.6.080604.162305","article-title":"Noonan syndrome and related disorders: genetics and pathogenesis","volume":"6","author":"Tartaglia","year":"2005","journal-title":"Annu. Rev. Genomics Hum. Genet."},{"issue":"4","key":"10.1016\/j.bone.2021.116060_bb0225","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s11154-006-9021-1","article-title":"Noonan syndrome and related disorders: alterations in growth and puberty","volume":"7","author":"Noonan","year":"2006","journal-title":"Rev. Endocr. Metab. Disord."},{"issue":"4","key":"10.1016\/j.bone.2021.116060_bb0230","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/ng772","article-title":"Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome","volume":"29","author":"Tartaglia","year":"2001","journal-title":"Nat. Genet."},{"issue":"1","key":"10.1016\/j.bone.2021.116060_bb0235","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/ng1926","article-title":"Germline gain-of-function mutations in SOS1 cause Noonan syndrome","volume":"39","author":"Roberts","year":"2007","journal-title":"Nat. Genet."},{"issue":"1","key":"10.1016\/j.bone.2021.116060_bb0240","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/ng1939","article-title":"Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome","volume":"39","author":"Tartaglia","year":"2007","journal-title":"Nat. Genet."},{"issue":"8","key":"10.1016\/j.bone.2021.116060_bb0245","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1038\/ng2073","article-title":"Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy","volume":"39","author":"Pandit","year":"2007","journal-title":"Nat. Genet."},{"issue":"8","key":"10.1016\/j.bone.2021.116060_bb0250","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/ng2078","article-title":"Germline gain-of-function mutations in RAF1 cause Noonan syndrome","volume":"39","author":"Razzaque","year":"2007","journal-title":"Nat. Genet."},{"issue":"1","key":"10.1016\/j.bone.2021.116060_bb0255","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ajhg.2013.05.021","article-title":"Gain-of-function mutations in RIT1 cause Noonan syndrome, a RAS\/MAPK pathway syndrome","volume":"93","author":"Aoki","year":"2013","journal-title":"Am. J. Hum. Genet."},{"issue":"3","key":"10.1016\/j.bone.2021.116060_bb0260","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/ng1748","article-title":"Germline KRAS mutations cause Noonan syndrome","volume":"38","author":"Schubbert","year":"2006","journal-title":"Nat. Genet."},{"issue":"1","key":"10.1016\/j.bone.2021.116060_bb0265","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/ng.497","article-title":"A restricted spectrum of NRAS mutations causes Noonan syndrome","volume":"42","author":"Cirstea","year":"2010","journal-title":"Nat. Genet."},{"issue":"9","key":"10.1016\/j.bone.2021.116060_bb0270","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/ng.425","article-title":"Mutation of SHOC2 promotes aberrant protein N-myristoylation and causes Noonan-like syndrome with loose anagen hair","volume":"41","author":"Cordeddu","year":"2009","journal-title":"Nat. Genet."},{"issue":"2","key":"10.1016\/j.bone.2021.116060_bb0275","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.ajhg.2010.06.015","article-title":"Heterozygous germline mutations in the CBL tumor-suppressor gene cause a Noonan syndrome-like phenotype","volume":"87","author":"Martinelli","year":"2010","journal-title":"Am. J. Hum. Genet."},{"issue":"4","key":"10.1016\/j.bone.2021.116060_bb0280","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1159\/000502741","article-title":"LZTR1: genotype expansion in Noonan syndrome","volume":"92","author":"Guemes","year":"2019","journal-title":"Horm. Res. Paediatr."},{"key":"10.1016\/j.bone.2021.116060_bb0285","series-title":"GeneReviews((R)). Seattle (WA)","article-title":"Noonan Syndrome with Multiple Lentigines","author":"Gelb","year":"1993"},{"issue":"4","key":"10.1016\/j.bone.2021.116060_bb0290","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/humu.20955","article-title":"Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: molecular diversity and associated phenotypic spectrum","volume":"30","author":"Sarkozy","year":"2009","journal-title":"Hum. Mutat."},{"issue":"2","key":"10.1016\/j.bone.2021.116060_bb0295","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/ajmg.c.30296","article-title":"The musculoskeletal phenotype of the RASopathies","volume":"157C","author":"Stevenson","year":"2011","journal-title":"Am. J. Med. Genet. C: Semin. Med. Genet."},{"issue":"2","key":"10.1016\/j.bone.2021.116060_bb0300","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s12105-010-0178-2","article-title":"Giant cell lesions in noonan syndrome: case report and review of the literature","volume":"4","author":"Bufalino","year":"2010","journal-title":"Head Neck Pathol."},{"issue":"4","key":"10.1016\/j.bone.2021.116060_bb0305","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/ejhg.2008.188","article-title":"Multiple giant cell lesions in patients with Noonan syndrome and cardio-facio-cutaneous syndrome","volume":"17","author":"Neumann","year":"2009","journal-title":"Eur. J. Hum. Genet."},{"issue":"2","key":"10.1016\/j.bone.2021.116060_bb0310","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/ajmg.1320400208","article-title":"Noonan-like\/multiple giant cell lesion syndrome","volume":"40","author":"Cohen","year":"1991","journal-title":"Am. J. Med. Genet."},{"issue":"1","key":"10.1016\/j.bone.2021.116060_bb0315","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/ajmg.a.20502","article-title":"Adult height in Noonan syndrome","volume":"123A","author":"Noonan","year":"2003","journal-title":"Am. J. Med. Genet. A"},{"issue":"3","key":"10.1016\/j.bone.2021.116060_bb0320","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/BF00441408","article-title":"Noonan syndrome: growth and clinical manifestations in 144 cases","volume":"148","author":"Ranke","year":"1988","journal-title":"Eur. J. Pediatr."},{"issue":"2","key":"10.1016\/j.bone.2021.116060_bb0325","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1136\/adc.2006.104547","article-title":"The natural history of Noonan syndrome: a long-term follow-up study","volume":"92","author":"Shaw","year":"2007","journal-title":"Arch. Dis. Child."},{"issue":"12","key":"10.1016\/j.bone.2021.116060_bb0330","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1002\/ajmg.a.35639","article-title":"Medical complications, clinical findings, and educational outcomes in adults with Noonan syndrome","volume":"158A","author":"Smpokou","year":"2012","journal-title":"Am. J. Med. Genet. A"},{"issue":"Suppl. 2","key":"10.1016\/j.bone.2021.116060_bb0335","first-page":"64","article-title":"Noonan syndrome, the Ras-MAPK signalling pathway and short stature","volume":"71","author":"Binder","year":"2009","journal-title":"Horm. Res."},{"key":"10.1016\/j.bone.2021.116060_bb0340","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1159\/000341739","article-title":"Spectrum of insulin-like growth factor deficiency","volume":"23","author":"Wit","year":"2012","journal-title":"Endocr. Dev."},{"issue":"1","key":"10.1016\/j.bone.2021.116060_bb0345","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1159\/000498859","article-title":"Treatment with growth hormone in Noonan syndrome observed during 25 years of KIGS: near adult height and outcome prediction","volume":"91","author":"Ranke","year":"2019","journal-title":"Horm. Res. Paediatr."},{"issue":"5","key":"10.1016\/j.bone.2021.116060_bb0350","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1136\/adc.84.5.440","article-title":"Short stature in Noonan syndrome: response to growth hormone therapy","volume":"84","author":"Kirk","year":"2001","journal-title":"Arch. Dis. Child."},{"issue":"5","key":"10.1016\/j.bone.2021.116060_bb0355","first-page":"1953","article-title":"Growth hormone therapy and growth in children with Noonan\u2019s syndrome: results of 3 years\u2019 follow-up","volume":"86","author":"MacFarlane","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"10.1016\/j.bone.2021.116060_bb0360","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/humu.21187","article-title":"Molecular and clinical analysis of RAF1 in Noonan syndrome and related disorders: dephosphorylation of serine 259 as the essential mechanism for mutant activation","volume":"31","author":"Kobayashi","year":"2010","journal-title":"Hum. Mutat."},{"issue":"6","key":"10.1016\/j.bone.2021.116060_bb0365","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jpeds.2011.05.024","article-title":"Spectrum of mutations in Noonan syndrome and their correlation with phenotypes","volume":"159","author":"Lee","year":"2011","journal-title":"J. Pediatr."},{"issue":"2","key":"10.1016\/j.bone.2021.116060_bb0370","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1136\/adc.67.2.178","article-title":"A clinical study of Noonan syndrome","volume":"67","author":"Sharland","year":"1992","journal-title":"Arch. Dis. Child."},{"issue":"10","key":"10.1016\/j.bone.2021.116060_bb0375","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.2106\/00004623-200110000-00006","article-title":"Spinal deformities in Noonan syndrome: a clinical review of sixty cases","volume":"83","author":"Lee","year":"2001","journal-title":"J. Bone Joint Surg. Am."},{"issue":"1","key":"10.1016\/j.bone.2021.116060_bb0380","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.beem.2010.09.002","article-title":"Noonan syndrome and clinically related disorders","volume":"25","author":"Tartaglia","year":"2011","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"issue":"3","key":"10.1016\/j.bone.2021.116060_bb0385","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/ajmg.a.34419","article-title":"Characterization of a novel KRAS mutation identified in Noonan syndrome","volume":"158A","author":"Razzaque","year":"2012","journal-title":"Am. J. Med. Genet. A"},{"issue":"1","key":"10.1016\/j.bone.2021.116060_bb0390","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1136\/jmg.24.1.9","article-title":"Noonan syndrome","volume":"24","author":"Allanson","year":"1987","journal-title":"J. Med. Genet."},{"issue":"2","key":"10.1016\/j.bone.2021.116060_bb0395","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ymgme.2012.04.003","article-title":"Decreased bone mineralization in children with Noonan syndrome: another consequence of dysregulated RAS MAPKinase pathway?","volume":"106","author":"Choudhry","year":"2012","journal-title":"Mol. Genet. Metab."},{"issue":"6","key":"10.1016\/j.bone.2021.116060_bb0400","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/j.1399-0004.2010.01619.x","article-title":"Bone resorption in syndromes of the Ras\/MAPK pathway","volume":"80","author":"Stevenson","year":"2011","journal-title":"Clin. Genet."},{"issue":"Suppl. 1","key":"10.1016\/j.bone.2021.116060_bb0405","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/ocr.12144","article-title":"A review of craniofacial and dental findings of the RASopathies","volume":"20","author":"Cao","year":"2017","journal-title":"Orthod. Craniofacial Res."},{"issue":"6","key":"10.1016\/j.bone.2021.116060_bb0410","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/archpedi.1969.02100030654006","article-title":"Multiple lentigenes syndrome","volume":"117","author":"Gorlin","year":"1969","journal-title":"Am. J. Dis. Child"},{"issue":"2","key":"10.1016\/j.bone.2021.116060_bb0415","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1086\/341528","article-title":"Grouping of multiple-lentigines\/LEOPARD and Noonan syndromes on the PTPN11 gene","volume":"71","author":"Digilio","year":"2002","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.bone.2021.116060_bb0420","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1750-1172-3-13","article-title":"Leopard syndrome","volume":"3","author":"Sarkozy","year":"2008","journal-title":"Orphanet. J. Rare Dis."},{"issue":"3","key":"10.1016\/j.bone.2021.116060_bb0425","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s10689-011-9446-x","article-title":"The differential diagnosis of familial lentiginosis syndromes","volume":"10","author":"Lodish","year":"2011","journal-title":"Familial Cancer"},{"issue":"2","key":"10.1016\/j.bone.2021.116060_bb0430","article-title":"Noonan syndrome and related disorders: dysregulated RAS-mitogen activated protein kinase signal transduction","volume":"15","author":"Gelb","year":"2006","journal-title":"Hum. Mol. Genet."},{"issue":"3","key":"10.1016\/j.bone.2021.116060_bb0435","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/0002-9343(76)90764-6","article-title":"Multiple lentigines syndrome. Case report and review of the literature","volume":"60","author":"Voron","year":"1976","journal-title":"Am. J. Med."},{"issue":"7","key":"10.1016\/j.bone.2021.116060_bb0440","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/ajmg.a.31156","article-title":"LEOPARD syndrome: clinical diagnosis in the first year of life","volume":"140","author":"Digilio","year":"2006","journal-title":"Am. J. Med. Genet. A"},{"issue":"5","key":"10.1016\/j.bone.2021.116060_bb0445","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1530\/EJE-15-0922","article-title":"Growth patterns of patients with Noonan syndrome: correlation with age and genotype","volume":"174","author":"Cessans","year":"2016","journal-title":"Eur. J. Endocrinol."},{"issue":"8","key":"10.1016\/j.bone.2021.116060_bb0450","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1002\/ajmg.a.61203","article-title":"RAF1 variant in a patient with Noonan syndrome with multiple lentigines and craniosynostosis","volume":"179","author":"Rodriguez","year":"2019","journal-title":"Am. J. Med. Genet. A"},{"issue":"3","key":"10.1016\/j.bone.2021.116060_bb0455","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/ced.13329","article-title":"Noonan syndrome with multiple lentigines and associated craniosynostosis","volume":"43","author":"McDonald","year":"2018","journal-title":"Clin. Exp. Dermatol."},{"issue":"10","key":"10.1016\/j.bone.2021.116060_bb0460","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1038\/s41431-018-0196-1","article-title":"Expanding the clinical and molecular findings in RASA1 capillary malformation-arteriovenous malformation","volume":"26","author":"Wooderchak-Donahue","year":"2018","journal-title":"Eur. J. Hum. Genet."},{"issue":"4","key":"10.1016\/j.bone.2021.116060_bb0465","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/pde.12112","article-title":"Capillary malformation--arteriovenous malformation syndrome: review of the literature, proposed diagnostic criteria, and recommendations for management","volume":"30","author":"Orme","year":"2013","journal-title":"Pediatr. Dermatol."},{"issue":"4","key":"10.1016\/j.bone.2021.116060_bb0470","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/ijd.12040","article-title":"Capillary malformation-arteriovenous malformation: a clinical review of 45 patients","volume":"53","author":"Larralde","year":"2014","journal-title":"Int. J. Dermatol."},{"issue":"6","key":"10.1016\/j.bone.2021.116060_bb0475","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1086\/379793","article-title":"Capillary malformation-arteriovenous malformation, a new clinical and genetic disorder caused by RASA1 mutations","volume":"73","author":"Eerola","year":"2003","journal-title":"Am. J. Hum. Genet."},{"issue":"1","key":"10.1016\/j.bone.2021.116060_bb0480","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/jmedgenet-2019-106024","article-title":"RASA1 mosaic mutations in patients with capillary malformation-arteriovenous malformation","volume":"57","author":"Revencu","year":"2020","journal-title":"J. Med. Genet."},{"issue":"7","key":"10.1016\/j.bone.2021.116060_bb0485","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00403-008-0842-5","article-title":"A novel mutation in RASA1 causes capillary malformation and limb enlargement","volume":"300","author":"Hershkovitz","year":"2008","journal-title":"Arch. Dermatol. Res."},{"issue":"5","key":"10.1016\/j.bone.2021.116060_bb0490","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1002\/ajmg.a.35292","article-title":"Costello, Japan CFCssgi. Prevalence and clinical features of Costello syndrome and cardio-facio-cutaneous syndrome in Japan: findings from a nationwide epidemiological survey","volume":"158A","author":"Abe","year":"2012","journal-title":"Am. J. Med. Genet. A"},{"issue":"9","key":"10.1016\/j.bone.2021.116060_bb0495","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/ajmg.a.61270","article-title":"Costello syndrome: clinical phenotype, genotype, and management guidelines","volume":"179","author":"Gripp","year":"2019","journal-title":"Am. J. Med. Genet. A"},{"issue":"1","key":"10.1016\/j.bone.2021.116060_bb0500","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/ajmg.c.10019","article-title":"Costello syndrome: an overview","volume":"117C","author":"Hennekam","year":"2003","journal-title":"Am. J. Med. Genet. C: Semin. Med. Genet."},{"issue":"2","key":"10.1016\/j.bone.2021.116060_bb0505","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1399-0004.2007.00743.x","article-title":"HRAS and the Costello syndrome","volume":"71","author":"Rauen","year":"2007","journal-title":"Clin. Genet."},{"issue":"10","key":"10.1016\/j.bone.2021.116060_bb0510","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1038\/ng1641","article-title":"Germline mutations in HRAS proto-oncogene cause Costello syndrome","volume":"37","author":"Aoki","year":"2005","journal-title":"Nat. Genet."},{"issue":"3","key":"10.1016\/j.bone.2021.116060_bb0515","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1086\/302829","article-title":"Decreased elastin deposition and high proliferation of fibroblasts from Costello syndrome are related to functional deficiency in the 67-kD elastin-binding protein","volume":"66","author":"Hinek","year":"2000","journal-title":"Am. J. Hum. Genet."},{"issue":"1","key":"10.1016\/j.bone.2021.116060_bb0520","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/01241398-200301000-00019","article-title":"Costello syndrome: orthopaedic manifestations and functional health","volume":"23","author":"Yassir","year":"2003","journal-title":"J. Pediatr. Orthop."},{"issue":"5","key":"10.1016\/j.bone.2021.116060_bb0525","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/BPO.0b013e318220396e","article-title":"Orthopaedic conditions in Ras\/MAPK related disorders","volume":"31","author":"Reinker","year":"2011","journal-title":"J. Pediatr. Orthop."},{"issue":"8","key":"10.1016\/j.bone.2021.116060_bb0530","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1002\/ajmg.a.36047","article-title":"Orthopedic manifestations and implications for individuals with Costello syndrome","volume":"161A","author":"Detweiler","year":"2013","journal-title":"Am. J. Med. Genet. A"},{"issue":"2","key":"10.1016\/j.bone.2021.116060_bb0535","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/ajmg.a.30187","article-title":"Growth hormone deficiency in Costello syndrome","volume":"129A","author":"Stein","year":"2004","journal-title":"Am. J. Med. Genet. A"},{"issue":"2","key":"10.1016\/j.bone.2021.116060_bb0540","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/ajmg.a.30747","article-title":"The adult phenotype in Costello syndrome","volume":"136","author":"White","year":"2005","journal-title":"Am. J. Med. Genet. A"},{"issue":"6","key":"10.1016\/j.bone.2021.116060_bb0545","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1002\/ajmg.a.36475","article-title":"Craniofacial and dental development in Costello syndrome","volume":"164A","author":"Goodwin","year":"2014","journal-title":"Am. J. Med. Genet. A"},{"issue":"7","key":"10.1016\/j.bone.2021.116060_bb0550","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1136\/jmg.2007.049270","article-title":"Myopathy caused by HRAS germline mutations: implications for disturbed myogenic differentiation in the presence of constitutive HRas activation","volume":"44","author":"van der Burgt","year":"2007","journal-title":"J. Med. Genet."},{"issue":"3","key":"10.1016\/j.bone.2021.116060_bb0555","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/ajmg.1320250303","article-title":"New multiple congenital anomalies\/mental retardation syndrome with cardio-facio-cutaneous involvement--the CFC syndrome","volume":"25","author":"Reynolds","year":"1986","journal-title":"Am. J. Med. Genet."},{"issue":"4","key":"10.1016\/j.bone.2021.116060_bb0560","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2013-3189","article-title":"Cardio-facio-cutaneous syndrome: clinical features, diagnosis, and management guidelines","volume":"134","author":"Pierpont","year":"2014","journal-title":"Pediatrics"},{"key":"10.1016\/j.bone.2021.116060_bb0565","series-title":"GeneReviews((R)). Seattle (WA)","article-title":"Cardiofaciocutaneous Syndrome","author":"Rauen","year":"1993"},{"issue":"12","key":"10.1016\/j.bone.2021.116060_bb0570","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1111\/j.1469-8749.2007.00894.x","article-title":"Neurological complications of cardio-facio-cutaneous syndrome","volume":"49","author":"Yoon","year":"2007","journal-title":"Dev. Med. Child Neurol."},{"issue":"4","key":"10.1016\/j.bone.2021.116060_bb0575","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1136\/jmg.2007.054460","article-title":"Further delineation of cardio-facio-cutaneous syndrome: clinical features of 38 individuals with proven mutations","volume":"45","author":"Armour","year":"2008","journal-title":"J. Med. Genet."},{"issue":"3","key":"10.1016\/j.bone.2021.116060_bb0580","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/ng1749","article-title":"Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome","volume":"38","author":"Niihori","year":"2006","journal-title":"Nat. Genet."},{"issue":"5765","key":"10.1016\/j.bone.2021.116060_bb0585","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1126\/science.1124642","article-title":"Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome","volume":"311","author":"Rodriguez-Viciana","year":"2006","journal-title":"Science."},{"issue":"2","key":"10.1016\/j.bone.2021.116060_bb0590","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/ajmg.c.30295","article-title":"Cardio-facio-cutaneous syndrome: does genotype predict phenotype?","volume":"157C","author":"Allanson","year":"2011","journal-title":"Am. J. Med. Genet. C: Semin. Med. Genet."},{"issue":"13","key":"10.1016\/j.bone.2021.116060_bb0595","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1002\/ajmg.a.31815","article-title":"Further delineation of the phenotype resulting from BRAF or MEK1 germline mutations helps differentiate cardio-facio-cutaneous syndrome from Costello syndrome","volume":"143A","author":"Gripp","year":"2007","journal-title":"Am. J. Med. Genet. A"},{"issue":"6","key":"10.1016\/j.bone.2021.116060_bb0600","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/j.1365-4632.2004.02102.x","article-title":"Cardio-facio-cutaneous syndrome: report of a case with a review of the literature","volume":"43","author":"Nanda","year":"2004","journal-title":"Int. J. Dermatol."},{"issue":"3","key":"10.1016\/j.bone.2021.116060_bb0605","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1055\/s-0030-1262840","article-title":"Cardio-facio-cutaneous syndrome: phenotypic variability and differential diagnosis in 3 cases with de novo BRAF mutations","volume":"41","author":"Demir","year":"2010","journal-title":"Neuropediatrics."},{"issue":"6","key":"10.1016\/j.bone.2021.116060_bb0610","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/cge.12005","article-title":"Craniofacial and dental development in cardio-facio-cutaneous syndrome: the importance of Ras signaling homeostasis","volume":"83","author":"Goodwin","year":"2013","journal-title":"Clin. Genet."},{"key":"10.1016\/j.bone.2021.116060_bb0615","doi-asserted-by":"crossref","first-page":"144369","DOI":"10.1016\/j.gene.2020.144369","article-title":"Cardio-facio-cutaneous syndrome-associated pathogenic MAP2K1 variants activate autophagy","volume":"733","author":"Chen","year":"2020","journal-title":"Gene."},{"issue":"9","key":"10.1016\/j.bone.2021.116060_bb0620","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1038\/ng2113","article-title":"Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1-like phenotype","volume":"39","author":"Brems","year":"2007","journal-title":"Nat. Genet."},{"issue":"7","key":"10.1016\/j.bone.2021.116060_bb0625","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1136\/jmg.2008.065243","article-title":"SPRED1 germline mutations caused a neurofibromatosis type 1 overlapping phenotype","volume":"46","author":"Pasmant","year":"2009","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.bone.2021.116060_bb0630","unstructured":"Legius E, Stevenson D. Legius Syndrome. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews((R)). Seattle (WA)1993."},{"issue":"2","key":"10.1016\/j.bone.2021.116060_bb0635","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/ajmg.c.30297","article-title":"Observations on intelligence and behavior in 15 patients with Legius syndrome","volume":"157C","author":"Denayer","year":"2011","journal-title":"Am. J. Med. Genet. C: Semin. Med. Genet."},{"issue":"4","key":"10.1016\/j.bone.2021.116060_bb0640","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2302\/kjm.2013-0002-RE","article-title":"Legius syndrome, an update. Molecular pathology of mutations in SPRED1","volume":"62","author":"Brems","year":"2013","journal-title":"Keio J. Med."},{"issue":"1","key":"10.1016\/j.bone.2021.116060_bb0645","doi-asserted-by":"crossref","DOI":"10.1002\/humu.21404","article-title":"Legius syndrome in fourteen families","volume":"32","author":"Denayer","year":"2011","journal-title":"Hum. Mutat."},{"issue":"19","key":"10.1016\/j.bone.2021.116060_bb0650","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2009.1663","article-title":"Clinical and mutational spectrum of neurofibromatosis type 1-like syndrome","volume":"302","author":"Messiaen","year":"2009","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.bone.2021.116060_bb0655","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1002\/humu.22152","article-title":"Review and update of SPRED1 mutations causing Legius syndrome","volume":"33","author":"Brems","year":"2012","journal-title":"Hum. Mutat."},{"issue":"5","key":"10.1016\/j.bone.2021.116060_bb0660","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.bone.2005.01.022","article-title":"Neurofibromin and its inactivation of Ras are prerequisites for osteoblast functioning","volume":"36","author":"Yu","year":"2005","journal-title":"Bone."},{"issue":"8","key":"10.1016\/j.bone.2021.116060_bb0665","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1093\/hmg\/ddm032","article-title":"Multiple roles for neurofibromin in skeletal development and growth","volume":"16","author":"Kolanczyk","year":"2007","journal-title":"Hum. Mol. Genet."},{"issue":"4","key":"10.1016\/j.bone.2021.116060_bb0670","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.bone.2012.07.011","article-title":"Deterioration of fracture healing in the mouse model of NF1 long bone dysplasia","volume":"51","author":"El Khassawna","year":"2012","journal-title":"Bone."},{"issue":"14","key":"10.1016\/j.bone.2021.116060_bb0675","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1093\/hmg\/ddr149","article-title":"Neurofibromin (Nf1) is required for skeletal muscle development","volume":"20","author":"Kossler","year":"2011","journal-title":"Hum. Mol. Genet."},{"issue":"8","key":"10.1016\/j.bone.2021.116060_bb0680","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/nm.3583","article-title":"Asfotase-alpha improves bone growth, mineralization and strength in mouse models of neurofibromatosis type-1","volume":"20","author":"de la Croix","year":"2014","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.bone.2021.116060_bb0685","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/j.bone.2011.03.760","article-title":"Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model","volume":"48","author":"Zhang","year":"2011","journal-title":"Bone"},{"issue":"6","key":"10.1016\/j.bone.2021.116060_bb0690","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.cmet.2006.10.010","article-title":"ATF4 mediation of NF1 functions in osteoblast reveals a nutritional basis for congenital skeletal dysplasiae","volume":"4","author":"Elefteriou","year":"2006","journal-title":"Cell Metab."},{"issue":"8","key":"10.1016\/j.bone.2021.116060_bb0695","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1002\/jbmr.3155","article-title":"Targeted disruption of NF1 in osteocytes increases FGF23 and osteoid with Osteomalacia-like bone phenotype","volume":"32","author":"Kamiya","year":"2017","journal-title":"J. Bone Miner. Res."},{"issue":"8","key":"10.1016\/j.bone.2021.116060_bb0700","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/nm1084","article-title":"Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation","volume":"10","author":"Araki","year":"2004","journal-title":"Nat. Med."},{"issue":"11","key":"10.1016\/j.bone.2021.116060_bb0705","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.1073\/pnas.1119803109","article-title":"Noonan syndrome-causing SHP2 mutants inhibit insulin-like growth factor 1 release via growth hormone-induced ERK hyperactivation, which contributes to short stature","volume":"109","author":"De Rocca","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"13","key":"10.1016\/j.bone.2021.116060_bb0710","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1093\/hmg\/ddy133","article-title":"Noonan syndrome-causing SHP2 mutants impair ERK-dependent chondrocyte differentiation during endochondral bone growth","volume":"27","author":"Tajan","year":"2018","journal-title":"Hum. Mol. Genet."},{"issue":"36","key":"10.1016\/j.bone.2021.116060_bb0715","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.0903302106","article-title":"Noonan syndrome is associated with enhanced pERK activity, the repression of which can prevent craniofacial malformations","volume":"106","author":"Nakamura","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"46","key":"10.1016\/j.bone.2021.116060_bb0720","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1418126111","article-title":"K-RasV14I recapitulates Noonan syndrome in mice","volume":"111","author":"Hernandez-Porras","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"21","key":"10.1016\/j.bone.2021.116060_bb0725","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.140495","article-title":"KrasP34R and KrasT58I mutations induce distinct RASopathy phenotypes in mice","volume":"5","author":"Wong","year":"2020","journal-title":"JCI Insight"},{"issue":"12","key":"10.1016\/j.bone.2021.116060_bb0730","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.0030225","article-title":"Shp2 knockdown and Noonan\/LEOPARD mutant Shp2-induced gastrulation defects","volume":"3","author":"Jopling","year":"2007","journal-title":"PLoS Genet."},{"issue":"3","key":"10.1016\/j.bone.2021.116060_bb0735","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1242\/dmm.007112","article-title":"Noonan syndrome gain-of-function mutations in NRAS cause zebrafish gastrulation defects","volume":"4","author":"Runtuwene","year":"2011","journal-title":"Dis. Model. Mech."},{"issue":"5","key":"10.1016\/j.bone.2021.116060_bb0740","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.devcel.2010.03.009","article-title":"Phosphatase-dependent and -independent functions of Shp2 in neural crest cells underlie LEOPARD syndrome pathogenesis","volume":"18","author":"Stewart","year":"2010","journal-title":"Dev. Cell"},{"issue":"19","key":"10.1016\/j.bone.2021.116060_bb0745","doi-asserted-by":"crossref","first-page":"7979","DOI":"10.1073\/pnas.0900343106","article-title":"Endogenous expression of Hras(G12V) induces developmental defects and neoplasms with copy number imbalances of the oncogene","volume":"106","author":"Chen","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6","key":"10.1016\/j.bone.2021.116060_bb0750","first-page":"2169","article-title":"A mouse model for Costello syndrome reveals an Ang II-mediated hypertensive condition","volume":"118","author":"Schuhmacher","year":"2008","journal-title":"J. Clin. Invest."},{"issue":"3","key":"10.1016\/j.bone.2021.116060_bb0755","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1093\/hmg\/ddt455","article-title":"Abnormal Ras signaling in Costello syndrome (CS) negatively regulates enamel formation","volume":"23","author":"Goodwin","year":"2014","journal-title":"Hum. Mol. Genet."},{"issue":"17","key":"10.1016\/j.bone.2021.116060_bb0760","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1101\/gad.193458.112","article-title":"The intermediate-activity (L597V)BRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF\/MEK\/ERK pathway","volume":"26","author":"Andreadi","year":"2012","journal-title":"Genes Dev."},{"issue":"12","key":"10.1016\/j.bone.2021.116060_bb0765","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1016933108","article-title":"Constitutive activation of B-Raf in the mouse germ line provides a model for human cardio-facio-cutaneous syndrome","volume":"108","author":"Urosevic","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"24","key":"10.1016\/j.bone.2021.116060_bb0770","doi-asserted-by":"crossref","first-page":"6553","DOI":"10.1093\/hmg\/ddu376","article-title":"New BRAF knockin mice provide a pathogenetic mechanism of developmental defects and a therapeutic approach in cardio-facio-cutaneous syndrome","volume":"23","author":"Inoue","year":"2014","journal-title":"Hum. Mol. Genet."},{"issue":"25","key":"10.1016\/j.bone.2021.116060_bb0775","doi-asserted-by":"crossref","first-page":"7349","DOI":"10.1093\/hmg\/ddv435","article-title":"Adult mice expressing a Braf Q241R mutation on an ICR\/CD-1 background exhibit a cardio-facio-cutaneous syndrome phenotype","volume":"24","author":"Moriya","year":"2015","journal-title":"Hum. Mol. Genet."},{"issue":"1","key":"10.1016\/j.bone.2021.116060_bb0780","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1093\/hmg\/ddy333","article-title":"C-type natriuretic peptide improves growth retardation in a mouse model of cardio-facio-cutaneous syndrome","volume":"28","author":"Inoue","year":"2019","journal-title":"Hum. Mol. Genet."},{"issue":"8","key":"10.1016\/j.bone.2021.116060_bb0785","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20081803","article-title":"The ERK MAPK pathway is essential for skeletal development and homeostasis","volume":"20","author":"Kim","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bone.2021.116060_bb0790","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2019.115106","article-title":"Constitutive activation of MEK1 in osteoprogenitors increases strength of bone despite impairing mineralization","volume":"130","author":"Fowlkes","year":"2020","journal-title":"Bone"},{"issue":"3","key":"10.1016\/j.bone.2021.116060_bb0795","article-title":"Mek1(Y130C) mice recapitulate aspects of human cardio-facio-cutaneous syndrome","volume":"11","author":"Aoidi","year":"2018","journal-title":"Dis. Model. Mech."},{"issue":"39","key":"10.1016\/j.bone.2021.116060_bb0800","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.RA120.013275","article-title":"Development of Noonan syndrome by deregulation of allosteric SOS autoactivation","volume":"295","author":"Umutesi","year":"2020","journal-title":"J. Biol. Chem."},{"issue":"36","key":"10.1016\/j.bone.2021.116060_bb0805","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1406559111","article-title":"Src promotes GTPase activity of Ras via tyrosine 32 phosphorylation","volume":"111","author":"Bunda","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.bone.2021.116060_bb0810","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41467-018-08115-8","article-title":"Tyrosyl phosphorylation of KRAS stalls GTPase cycle via alteration of switch I and II conformation","volume":"10","author":"Kano","year":"2019","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.bone.2021.116060_bb0815","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1093\/hmg\/ddy412","article-title":"Dominant Noonan syndrome-causing LZTR1 mutations specifically affect the Kelch domain substrate-recognition surface and enhance RAS-MAPK signaling","volume":"28","author":"Motta","year":"2019","journal-title":"Hum. Mol. Genet."},{"issue":"1","key":"10.1016\/j.bone.2021.116060_bb0820","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00439-018-1951-7","article-title":"Delineation of LZTR1 mutation-positive patients with Noonan syndrome and identification of LZTR1 binding to RAF1-PPP1CB complexes","volume":"138","author":"Umeki","year":"2019","journal-title":"Hum. Genet."},{"issue":"9","key":"10.1016\/j.bone.2021.116060_bb0825","doi-asserted-by":"crossref","DOI":"10.1002\/ajmg.a.37781","article-title":"A novel rasopathy caused by recurrent de novo missense mutations in PPP1CB closely resembles Noonan syndrome with loose anagen hair","volume":"170","author":"Gripp","year":"2016","journal-title":"Am. J. Med. Genet. A"},{"issue":"32","key":"10.1016\/j.bone.2021.116060_bb0830","doi-asserted-by":"crossref","first-page":"29819","DOI":"10.1074\/jbc.C300182200","article-title":"Protein kinase A blocks Raf-1 activity by stimulating 14-3-3 binding and blocking Raf-1 interaction with Ras","volume":"278","author":"Dumaz","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.bone.2021.116060_bb0835","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jmb.2012.08.009","article-title":"Synergistic binding of the phosphorylated S233- and S259-binding sites of C-RAF to one 14-3-3zeta dimer","volume":"423","author":"Molzan","year":"2012","journal-title":"J. Mol. Biol."},{"issue":"19","key":"10.1016\/j.bone.2021.116060_bb0840","doi-asserted-by":"crossref","first-page":"4698","DOI":"10.1128\/MCB.01636-09","article-title":"Impaired binding of 14-3-3 to C-RAF in Noonan syndrome suggests new approaches in diseases with increased Ras signaling","volume":"30","author":"Molzan","year":"2010","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.bone.2021.116060_bb0845","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3389\/fphys.2019.00388","article-title":"A YWHAZ variant associated with cardiofaciocutaneous syndrome activates the RAF-ERK pathway","volume":"10","author":"Popov","year":"2019","journal-title":"Front. Physiol."},{"issue":"5","key":"10.1016\/j.bone.2021.116060_bb0850","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/nrm3979","article-title":"Regulation of RAF protein kinases in ERK signalling","volume":"16","author":"Lavoie","year":"2015","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"7263","key":"10.1016\/j.bone.2021.116060_bb0855","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/nature08314","article-title":"A dimerization-dependent mechanism drives RAF catalytic activation","volume":"461","author":"Rajakulendran","year":"2009","journal-title":"Nature."},{"issue":"14","key":"10.1016\/j.bone.2021.116060_bb0860","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1093\/hmg\/ddp186","article-title":"Kinase-activating and kinase-impaired cardio-facio-cutaneous syndrome alleles have activity during zebrafish development and are sensitive to small molecule inhibitors","volume":"18","author":"Anastasaki","year":"2009","journal-title":"Hum. Mol. Genet."},{"issue":"29","key":"10.1016\/j.bone.2021.116060_bb0865","doi-asserted-by":"crossref","first-page":"27629","DOI":"10.1074\/jbc.M101727200","article-title":"Structure-based mutagenesis reveals distinct functions for Ras switch 1 and switch 2 in Sos-catalyzed guanine nucleotide exchange","volume":"276","author":"Hall","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.bone.2021.116060_bb0870","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/s40610-017-0059-5","article-title":"Control of the osteoblast lineage by mitogen-activated protein kinase signaling","volume":"3","author":"Franceschi","year":"2017","journal-title":"Curr. Mol. Biol. Rep."},{"issue":"5","key":"10.1016\/j.bone.2021.116060_bb0875","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1242\/dev.105536","article-title":"A pathway to bone: signaling molecules and transcription factors involved in chondrocyte development and maturation","volume":"142","author":"Kozhemyakina","year":"2015","journal-title":"Development"},{"issue":"10","key":"10.1016\/j.bone.2021.116060_bb0880","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19103004","article-title":"Roles of mitogen-activated protein kinases in osteoclast biology","volume":"19","author":"Lee","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"6847","key":"10.1016\/j.bone.2021.116060_bb0885","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/35088082","article-title":"Spred is a Sprouty-related suppressor of Ras signalling","volume":"412","author":"Wakioka","year":"2001","journal-title":"Nature."},{"issue":"13","key":"10.1016\/j.bone.2021.116060_bb0890","doi-asserted-by":"crossref","DOI":"10.1101\/gad.190876.112","article-title":"A shared molecular mechanism underlies the human rasopathies Legius syndrome and Neurofibromatosis-1","volume":"26","author":"Stowe","year":"2012","journal-title":"Genes Dev."},{"issue":"7","key":"10.1016\/j.bone.2021.116060_bb0895","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.M115.703710","article-title":"Interaction between a domain of the negative regulator of the Ras-ERK pathway, SPRED1 protein, and the GTPase-activating protein-related domain of neurofibromin is implicated in legius syndrome and neurofibromatosis Type 1","volume":"291","author":"Hirata","year":"2016","journal-title":"J. Biol. Chem."},{"issue":"10","key":"10.1016\/j.bone.2021.116060_bb0900","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2016.314","article-title":"Ras signaling regulates osteoprogenitor cell proliferation and bone formation","volume":"7","author":"Papaioannou","year":"2016","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.bone.2021.116060_bb0905","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1247\/csf.10001","article-title":"Potential involvement of Twist2 and Erk in the regulation of osteoblastogenesis by HB-EGF-EGFR signaling","volume":"35","author":"Nakamura","year":"2010","journal-title":"Cell Struct. Funct."},{"issue":"5","key":"10.1016\/j.bone.2021.116060_bb0910","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1359\/jbmr.2003.18.5.827","article-title":"Receptor tyrosine kinases inhibit bone morphogenetic protein-Smad responsive promoter activity and differentiation of murine MC3T3-E1 osteoblast-like cells","volume":"18","author":"Nakayama","year":"2003","journal-title":"J. Bone Miner. Res."},{"issue":"1\u20133","key":"10.1016\/j.bone.2021.116060_bb0915","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1159\/000204105","article-title":"Strontium promotes osteogenic differentiation of mesenchymal stem cells through the Ras\/MAPK signaling pathway","volume":"23","author":"Peng","year":"2009","journal-title":"Cell. Physiol. Biochem."},{"issue":"3","key":"10.1016\/j.bone.2021.116060_bb0920","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.yexcr.2009.09.028","article-title":"M-Ras is activated by bone morphogenetic protein-2 and participates in osteoblastic determination, differentiation, and transdifferentiation","volume":"316","author":"Watanabe-Takano","year":"2010","journal-title":"Exp. Cell Res."},{"issue":"1","key":"10.1016\/j.bone.2021.116060_bb0925","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1038\/s41598-021-82246-9","article-title":"Connective tissue growth factor promotes chemotaxis of preosteoblasts through integrin alpha5 and Ras during tensile force-induced intramembranous osteogenesis","volume":"11","author":"Jiang","year":"2021","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.bone.2021.116060_bb0930","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1002\/jcb.21249","article-title":"Mechanical stress-mediated Runx2 activation is dependent on Ras\/ERK1\/2 MAPK signaling in osteoblasts","volume":"101","author":"Kanno","year":"2007","journal-title":"J. Cell. Biochem."},{"issue":"8","key":"10.1016\/j.bone.2021.116060_bb0935","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/nrg1122","article-title":"Genetic regulation of osteoclast development and function","volume":"4","author":"Teitelbaum","year":"2003","journal-title":"Nat. Rev. Genet."},{"issue":"1","key":"10.1016\/j.bone.2021.116060_bb0940","doi-asserted-by":"crossref","DOI":"10.4068\/cmj.2016.52.1.12","article-title":"Signaling pathways in osteoclast differentiation","volume":"52","author":"Kim","year":"2016","journal-title":"Chonnam Med. J."},{"issue":"4","key":"10.1016\/j.bone.2021.116060_bb0945","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1002\/jcb.21719","article-title":"Pathway crosstalk between Ras\/Raf and PI3K in promotion of M-CSF-induced MEK\/ERK-mediated osteoclast survival","volume":"104","author":"Bradley","year":"2008","journal-title":"J. Cell. Biochem."},{"issue":"3","key":"10.1016\/j.bone.2021.116060_bb0950","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1074\/jbc.M508639200","article-title":"Mechanical inhibition of RANKL expression is regulated by H-Ras-GTPase","volume":"281","author":"Rubin","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"8","key":"10.1016\/j.bone.2021.116060_bb0955","doi-asserted-by":"crossref","DOI":"10.1038\/s41418-017-0050-y","article-title":"Non-canonical Wnt induces chondrocyte de-differentiation through Frizzled 6 and DVL-2\/B-raf\/CaMKIIalpha\/syndecan 4 axis","volume":"25","author":"Xie","year":"2018","journal-title":"Cell Death Differ."},{"issue":"12","key":"10.1016\/j.bone.2021.116060_bb0960","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18122591","article-title":"Impaired osteogenesis of disease-specific induced pluripotent stem cells derived from a CFC syndrome patient","volume":"18","author":"Choi","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bone.2021.116060_bb0965","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1128\/MCB.00617-07","article-title":"A-raf and B-raf are dispensable for normal endochondral bone development, and parathyroid hormone-related peptide suppresses extracellular signal-regulated kinase activation in hypertrophic chondrocytes","volume":"28","author":"Provot","year":"2008","journal-title":"Mol. Cell. Biol."},{"issue":"8","key":"10.1016\/j.bone.2021.116060_bb0970","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.M116.763342","article-title":"Raf kinases are essential for phosphate induction of ERK1\/2 phosphorylation in hypertrophic chondrocytes and normal endochondral bone development","volume":"292","author":"Papaioannou","year":"2017","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.bone.2021.116060_bb0975","first-page":"348","article-title":"c-Raf promotes angiogenesis during normal growth plate maturation","volume":"143","author":"Liu","year":"2016","journal-title":"Development"},{"issue":"8","key":"10.1016\/j.bone.2021.116060_bb0980","doi-asserted-by":"crossref","DOI":"10.1210\/me.2012-1063","article-title":"BDNF alters ERK\/p38 MAPK activity ratios to promote differentiation in growth plate chondrocytes","volume":"26","author":"Hutchison","year":"2012","journal-title":"Mol. Endocrinol."},{"issue":"4","key":"10.1016\/j.bone.2021.116060_bb0985","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.bbrc.2016.05.141","article-title":"A-Raf and C-Raf differentially regulate mechanobiological response of osteoblasts to guide mechanical stress-induced differentiation","volume":"476","author":"Zhang","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"25","key":"10.1016\/j.bone.2021.116060_bb0990","doi-asserted-by":"crossref","first-page":"22191","DOI":"10.1074\/jbc.M110364200","article-title":"New signaling pathway for parathyroid hormone and cyclic AMP action on extracellular-regulated kinase and cell proliferation in bone cells. Checkpoint of modulation by cyclic AMP","volume":"277","author":"Fujita","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"42","key":"10.1016\/j.bone.2021.116060_bb0995","doi-asserted-by":"crossref","first-page":"30273","DOI":"10.1074\/jbc.274.42.30273","article-title":"The Raf-1\/MEK\/ERK pathway regulates the expression of the p21(Cip1\/Waf1) gene in chondrocytes","volume":"274","author":"Beier","year":"1999","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.bone.2021.116060_bb1000","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1096\/fj.201700672RR","article-title":"A ERK\/RSK-mediated negative feedback loop regulates M-CSF-evoked PI3K\/AKT activation in macrophages","volume":"32","author":"Wang","year":"2018","journal-title":"FASEB J."},{"issue":"1","key":"10.1016\/j.bone.2021.116060_bb1005","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41413-020-00129-7","article-title":"Targeted Ptpn11 deletion in mice reveals the essential role of SHP2 in osteoblast differentiation and skeletal homeostasis","volume":"9","author":"Wang","year":"2021","journal-title":"Bone Res."},{"issue":"3","key":"10.1016\/j.bone.2021.116060_bb1010","doi-asserted-by":"crossref","DOI":"10.1002\/jbmr.2062","article-title":"Targeted disruption of Shp2 in chondrocytes leads to metachondromatosis with multiple cartilaginous protrusions","volume":"29","author":"Kim","year":"2014","journal-title":"J. Bone Miner. Res."},{"issue":"5","key":"10.1016\/j.bone.2021.116060_bb1015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1004364","article-title":"SHP2 regulates chondrocyte terminal differentiation, growth plate architecture and skeletal cell fates","volume":"10","author":"Bowen","year":"2014","journal-title":"PLoS Genet."},{"issue":"6","key":"10.1016\/j.bone.2021.116060_bb1020","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1359\/JBMR.040130","article-title":"NF1 tumor suppressor protein and mRNA in skeletal tissues of developing and adult normal mouse and NF1-deficient embryos","volume":"19","author":"Kuorilehto","year":"2004","journal-title":"J. Bone Miner. Res."},{"issue":"19","key":"10.1016\/j.bone.2021.116060_bb1025","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1093\/hmg\/ddl208","article-title":"Neurofibromin plays a critical role in modulating osteoblast differentiation of mesenchymal stem\/progenitor cells","volume":"15","author":"Wu","year":"2006","journal-title":"Hum. Mol. Genet."},{"issue":"23","key":"10.1016\/j.bone.2021.116060_bb1030","doi-asserted-by":"crossref","DOI":"10.1093\/hmg\/ddt333","article-title":"Hyperactive Ras\/MAPK signaling is critical for tibial nonunion fracture in neurofibromin-deficient mice","volume":"22","author":"Sharma","year":"2013","journal-title":"Hum. Mol. Genet."},{"issue":"6","key":"10.1016\/j.bone.2021.116060_bb1035","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.bone.2011.09.043","article-title":"JNK inhibitors increase osteogenesis in Nf1-deficient cells","volume":"49","author":"Sullivan","year":"2011","journal-title":"Bone."},{"issue":"9","key":"10.1016\/j.bone.2021.116060_bb1040","doi-asserted-by":"crossref","DOI":"10.1093\/hmg\/ddv019","article-title":"FGFR1 signaling in hypertrophic chondrocytes is attenuated by the Ras-GAP neurofibromin during endochondral bone formation","volume":"24","author":"Karolak","year":"2015","journal-title":"Hum. Mol. Genet."},{"issue":"20","key":"10.1016\/j.bone.2021.116060_bb1045","doi-asserted-by":"crossref","DOI":"10.1093\/hmg\/ddr310","article-title":"Mice lacking Nf1 in osteochondroprogenitor cells display skeletal dysplasia similar to patients with neurofibromatosis type I","volume":"20","author":"Wang","year":"2011","journal-title":"Hum. Mol. Genet."},{"issue":"15","key":"10.1016\/j.bone.2021.116060_bb1050","doi-asserted-by":"crossref","DOI":"10.1093\/hmg\/ddt162","article-title":"The ras-GTPase activity of neurofibromin restrains ERK-dependent FGFR signaling during endochondral bone formation","volume":"22","author":"Ono","year":"2013","journal-title":"Hum. Mol. Genet."},{"issue":"3","key":"10.1016\/j.bone.2021.116060_bb1055","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1101\/gad.1179104","article-title":"Constitutive activation of MEK1 in chondrocytes causes Stat1-independent achondroplasia-like dwarfism and rescues the Fgfr3-deficient mouse phenotype","volume":"18","author":"Murakami","year":"2004","journal-title":"Genes Dev."},{"issue":"1","key":"10.1016\/j.bone.2021.116060_bb1060","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s11914-016-0298-z","article-title":"Aberrant myeloid differentiation contributes to the development of osteoporosis in Neurofibromatosis Type 1","volume":"14","author":"Rhodes","year":"2016","journal-title":"Curr. Osteoporos. Rep."},{"issue":"10","key":"10.1016\/j.bone.2021.116060_bb1065","doi-asserted-by":"crossref","DOI":"10.1002\/jbmr.2538","article-title":"Nf1 haploinsufficiency alters myeloid lineage commitment and function, leading to deranged skeletal homeostasis","volume":"30","author":"Rhodes","year":"2015","journal-title":"J. Bone Miner. Res."},{"issue":"3","key":"10.1016\/j.bone.2021.116060_bb1070","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.bone.2010.06.001","article-title":"Osteoclasts in neurofibromatosis type 1 display enhanced resorption capacity, aberrant morphology, and resistance to serum deprivation","volume":"47","author":"Heerva","year":"2010","journal-title":"Bone."},{"issue":"11","key":"10.1016\/j.bone.2021.116060_bb1075","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1172\/JCI29092","article-title":"Hyperactivation of p21ras and PI3K cooperate to alter murine and human neurofibromatosis type 1-haploinsufficient osteoclast functions","volume":"116","author":"Yang","year":"2006","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.bone.2021.116060_bb1080","doi-asserted-by":"crossref","DOI":"10.1002\/ajmg.a.33965","article-title":"Multiple increased osteoclast functions in individuals with neurofibromatosis type 1","volume":"155A","author":"Stevenson","year":"2011","journal-title":"Am. J. Med. Genet. A"},{"issue":"2","key":"10.1016\/j.bone.2021.116060_bb1085","doi-asserted-by":"crossref","DOI":"10.1007\/s11033-020-06128-5","article-title":"Signaling pathways in human osteoclasts differentiation: ERK1\/2 as a key player","volume":"48","author":"Pennanen","year":"2021","journal-title":"Mol. Biol. Rep."},{"issue":"4","key":"10.1016\/j.bone.2021.116060_bb1090","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0171-9335(99)80058-2","article-title":"Rac-GTPase, osteoclast cytoskeleton and bone resorption","volume":"78","author":"Razzouk","year":"1999","journal-title":"Eur. J. Cell Biol."},{"issue":"12","key":"10.1016\/j.bone.2021.116060_bb1095","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1359\/JBMR.050816","article-title":"Regulation of osteoclast apoptosis and motility by small GTPase binding protein Rac1","volume":"20","author":"Fukuda","year":"2005","journal-title":"J. Bone Miner. Res."},{"issue":"12","key":"10.1016\/j.bone.2021.116060_bb1100","doi-asserted-by":"crossref","DOI":"10.1002\/jbmr.1992","article-title":"Hyperactive transforming growth factor-beta1 signaling potentiates skeletal defects in a neurofibromatosis type 1 mouse model","volume":"28","author":"Rhodes","year":"2013","journal-title":"J. Bone Miner. Res."},{"issue":"6","key":"10.1016\/j.bone.2021.116060_bb1105","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1203\/PDR.0b013e3181a1c607","article-title":"Ras dependent paracrine secretion of osteopontin by Nf1+\/- osteoblasts promote osteoclast activation in a neurofibromatosis type I murine model","volume":"65","author":"Li","year":"2009","journal-title":"Pediatr. Res."},{"issue":"5","key":"10.1016\/j.bone.2021.116060_bb1110","doi-asserted-by":"crossref","DOI":"10.1083\/jcb.200610046","article-title":"Critical role of the extracellular signal-regulated kinase-MAPK pathway in osteoblast differentiation and skeletal development","volume":"176","author":"Ge","year":"2007","journal-title":"J. Cell Biol."},{"issue":"1","key":"10.1016\/j.bone.2021.116060_bb1115","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1359\/jbmr.2002.17.1.101","article-title":"Bone morphogenetic proteins, extracellular matrix, and mitogen-activated protein kinase signaling pathways are required for osteoblast-specific gene expression and differentiation in MC3T3-E1 cells","volume":"17","author":"Xiao","year":"2002","journal-title":"J. Bone Miner. Res."},{"issue":"6","key":"10.1016\/j.bone.2021.116060_bb1120","doi-asserted-by":"crossref","first-page":"4453","DOI":"10.1074\/jbc.275.6.4453","article-title":"MAPK pathways activate and phosphorylate the osteoblast-specific transcription factor, Cbfa1","volume":"275","author":"Xiao","year":"2000","journal-title":"J. Biol. Chem."},{"issue":"Suppl. 1","key":"10.1016\/j.bone.2021.116060_bb1125","article-title":"Multiple signaling pathways converge on the Cbfa1\/Runx2 transcription factor to regulate osteoblast differentiation","volume":"44","author":"Franceschi","year":"2003","journal-title":"Connect. Tissue Res."},{"issue":"10","key":"10.1016\/j.bone.2021.116060_bb1130","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1359\/jbmr.2002.17.10.1785","article-title":"Continuous inhibition of MAPK signaling promotes the early osteoblastic differentiation and mineralization of the extracellular matrix","volume":"17","author":"Higuchi","year":"2002","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2021.116060_bb1135","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1196\/annals.1346.014","article-title":"M-CSF, c-Fms, and signaling in osteoclasts and their precursors","volume":"1068","author":"Ross","year":"2006","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"1","key":"10.1016\/j.bone.2021.116060_bb1140","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.molmed.2005.11.007","article-title":"RANKL-RANK signaling in osteoclastogenesis and bone disease","volume":"12","author":"Wada","year":"2006","journal-title":"Trends Mol. Med."},{"issue":"1","key":"10.1016\/j.bone.2021.116060_bb1145","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/jcp.20694","article-title":"The Cbl family proteins: ring leaders in regulation of cell signaling","volume":"209","author":"Swaminathan","year":"2006","journal-title":"J. Cell. Physiol."},{"issue":"2","key":"10.1016\/j.bone.2021.116060_bb1150","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S0012-1606(03)00299-9","article-title":"Deletion of the gene encoding c-Cbl alters the ability of osteoclasts to migrate, delaying resorption and ossification of cartilage during the development of long bones","volume":"261","author":"Chiusaroli","year":"2003","journal-title":"Dev. Biol."},{"key":"10.1016\/j.bone.2021.116060_bb1155","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2012.217","article-title":"E3 ubiquitin ligase-mediated regulation of bone formation and tumorigenesis","volume":"4","author":"Severe","year":"2013","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bone.2021.116060_bb1160","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2016.11.020","article-title":"Loss of Cbl-PI3K interaction modulates the periosteal response to fracture by enhancing osteogenic commitment and differentiation","volume":"95","author":"Scanlon","year":"2017","journal-title":"Bone"},{"issue":"6","key":"10.1016\/j.bone.2021.116060_bb1165","article-title":"An adjunctive use of asfotase alfa and zoledronic acid after spinal surgery in Neurofibromatosis Type 1 related dystrophic scoliosis","volume":"6","author":"Harindhanavudhi","year":"2020","journal-title":"AACE Clin. Case Rep."},{"issue":"1","key":"10.1016\/j.bone.2021.116060_bb1170","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jbmr.2316","article-title":"Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -\/- mice","volume":"30","author":"de la Croix","year":"2015","journal-title":"J. Bone Miner. Res."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328221002222?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328221002222?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T03:42:56Z","timestamp":1762659776000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328221002222"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":234,"alternative-id":["S8756328221002222"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2021.116060","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"RASopathies: The musculoskeletal consequences and their etiology and pathogenesis","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2021.116060","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116060"}}